Tilatamig samrotecan (AZD9592) is an ADC for the delivery of a topoisomerase I inhibitor (TOP1i) that targets epidermal growth factor receptor (EGFR) and c-MET and has anti-tumor activity. Tilatamig samrotecan (AZD9592) can induce DNA double-strand breaks, increase the expression of pRAD50 and γH2AX, and inhibit the growth of non-small cell lung cancer.

Physicochemical Properties

Synonyms	AZD9592
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	Topoisomerase I
References	[1]. Abstract 5737: Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate. Cancer research. (2023) 83 (7_Supplement): 5737. [2]. Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions. Antibodies (Basel). 2024 Oct 18;13(4):88.

Solubility Data